Biodexa gains license for polyposis asset as stock more than doubles [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
As per the agreement, Biodexa will hold exclusive rights to develop and commercialise eRapa globally, along with a $17m grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to help advance the candidate into a Phase III trial for familial adenomatous polyposis (FAP). Following the 26 April announcement, Biodexa's stock increased by 128.8%, raising the stock price from $0.73 at closing on 25 April, to $1.67 on 26 April when the markets opened. The asset is being evaluated in an ongoing Phase II study (NCT04230499), supported by a $3m grant from the CPRIT. In the trial, thirty patients with FAP who are undergoing endoscopic surveillance will be given eRapa at one of three escalating doses for a year. The primary endpoints of the study are safety and tolerability, with data expected to be presented in Q2 2024. Following a positive end of Phase II meeting with the US Food and Drug Administration (FDA), Emtora had announced plans to initiate a Phase III trial for
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- The New Menopause: Dr Mary Claire Haver On Shame And Stigma Free Aging [Forbes]Forbes
- Global Vertigo Treatment Market Forecast to Reach $1.6 Billion by 2030, Driven by the Rise in Benign Paroxysmal Positional Vertigo Prevalence [Yahoo! Finance]Yahoo! Finance
- FirstFT: Investors pull money from Starwood $10bn property fund [FT.com - Mergermarket]FT.com - Mergermarket
- FirstFT: Investors pull money from Starwood $10bn property fund [Financial Times (FT.com) (UK)]Financial Times
- Pfizer agrees to pay up to $250M to settle Zantac cancer lawsuits - report [Seeking Alpha]Seeking Alpha
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 5/9/24 - Form S-8
- 5/8/24 - Form 10-Q
- 5/1/24 - Form 4
- PFE's page on the SEC website